In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non–small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery

Volumn 144, Issue 5, 2012, Pages 1167-1175.e1

  Fahham, Duha ^a   Weiss, Ido D ^a   Abraham, Michal ^a,b   Beider, Katia ^a   Hanna, Wald ^a   Shlomai, Zippora ^a   Eizenberg, Orly ^b   Zamir, Gideon ^a   Izhar, Uzi ^a   Shapira, Oz M ^a   Peled, Amnon ^a   Wald, Ori ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Biokine Therapeutics   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BKT 140; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CISPLATIN; CYTOSTATIC AGENT; PHOSPHATE BUFFERED SALINE; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; BKT140; CXCL2 CHEMOKINE; CXCR4 PROTEIN, HUMAN; OLIGOPEPTIDE; PACLITAXEL;

A-549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON-SMALL CELL CARCINOMA CELL LINE; MOUSE; NCI-H460 CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; CHEMORADIOTHERAPY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL2; CHEMORADIOTHERAPY; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; OLIGOPEPTIDES; PACLITAXEL; RECEPTORS, CXCR4; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027918527     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2012.07.031     Document Type: Article

References (32)

1. Hubbard, M.O., Fu, P., Margevicius, S., Dowlati, A., Linden, P.A., Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival. J Thorac Cardiovasc Surg 143 (2012), 1307–1313.
2. Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA Cancer J Clin 60 (2010), 277–300.
3. Burger, J.A., Stewart, D.J., Wald, O., Peled, A., Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther 11 (2011), 621–630.
4. Balkwill, F.R., The chemokine system and cancer. J Pathol 226 (2012), 148–157.
5. Zlotnik, A., Burkhardt, A.M., Homey, B., Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 11 (2011), 597–606.
6. Beider, K., Abraham, M., Begin, M., Wald, H., Weiss, I.D., Wald, O., et al. Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS One, 4, 2009, e5125.
7. Burger, J.A., Kipps, T.J., CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107 (2006), 1761–1767.
8. Mantovani, A., Chemokines in neoplastic progression. Semin Cancer Biol 14 (2004), 147–148.
9. Spano, J.P., Andre, F., Morat, L., Sabatier, L., Besse, B., Combadiere, C., et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 15 (2004), 613–617.
10. Su, L., Zhang, J., Xu, H., Wang, Y., Chu, Y., Liu, R., et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res 11 (2005), 8273–8280.
11. Wagner, P.L., Hyjek, E., Vazquez, M.F., Meherally, D., Liu, Y.F., Chadwick, P.A., et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg 137 (2009), 615–621.
12. Phillips, R.J., Burdick, M.D., Lutz, M., Belperio, J.A., Keane, M.P., Strieter, R.M., The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167 (2003), 1676–1686.
13. Kirshberg, S., Izhar, U., Amir, G., Demma, J., Vernea, F., Beider, K., et al. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS One, 6, 2011, e24856.
14. Wald, O., Izhar, U., Amir, G., Avniel, S., Bar-Shavit, Y., Wald, H., et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol 177 (2006), 6983–6990.
15. Wald, O., Izhar, U., Amir, G., Kirshberg, S., Shlomai, Z., Zamir, G., et al. Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation. J Thorac Cardiovasc Surg 141 (2011), 1503–1512.
16. Bertolini, G., Roz, L., Perego, P., Tortoreto, M., Fontanella, E., Gatti, L., et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106 (2009), 16281–16286.
17. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene, February 27, 2012 [Epub ahead of print].
18. Peled, A., Wald, O., Burger, J., Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 21 (2012), 341–353.
19. Fujii, N., Nakashima, H., Tamamura, H., The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs 12 (2003), 185–195.
20. Tamamura, H., Xu, Y., Hattori, T., Zhang, X., Arakaki, R., Kanbara, K., et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 253 (1998), 877–882.
21. Jacobson, O., Weiss, I.D., Kiesewetter, D.O., Farber, J.M., Chen, X., PET of tumor CXCR4 expression with 4-18F-T140. J Nucl Med 51 (2010), 1796–1804.
22. Jacobson, O., Weiss, I.D., Szajek, L.P., Niu, G., Ma, Y., Kiesewetter, D.O., et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics 1 (2011), 251–262.
23. Beider, K., Begin, M., Abraham, M., Wald, H., Weiss, I.D., Wald, O., et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 39 (2011), 282–292.
24. Abraham, M., Beider, K., Wald, H., Weiss, I.D., Zipori, D., Galun, E., et al. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia 23 (2009), 1378–1388.
25. Abraham, M., Biyder, K., Begin, M., Wald, H., Weiss, I.D., Galun, E., et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 25 (2007), 2158–2166.
26. Chang, A., Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71 (2011), 3–10.
27. Burger, J.A., Peled, A., CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23 (2009), 43–52.
28. Rasheed, Z.A., Kowalski, J., Smith, B.D., Matsui, W., Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 29 (2011), 883–887.
29. Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15 (2008), 504–514.
30. Rivera, C., Rivera, S., Loriot, Y., Vozenin, M.C., Deutsch, E., Lung cancer stem cell: new insights on experimental models and preclinical data. J Oncol, 2011, 2011, 549181.
31. Sutherland, K.D., Berns, A., Cell of origin of lung cancer. Mol Oncol 4 (2010), 397–403.
32. DiPersio, J.F., Uy, G.L., Yasothan, U., Kirkpatrick, P., Plerixafor. Nat Rev Drug Discov 8 (2009), 105–106.